XML 29 R19.htm IDEA: XBRL DOCUMENT
v3.25.3

STOCKHOLDERS’ EQUITY (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Equity [Abstract] |
SUMMARY OF AGGREGATE COMMON STOCK SHARES ISSUED | SUMMARY OF AGGREGATE COMMON STOCK SHARES ISSUED
Nature |  | Shares |
Shares issued in connection with stock-based compensation |  |  | 396,768 |
Sales of common stock pursuant to the ATM Agreement |  |  | 5,384,868 | (*)
Total |  |  | 5,781,636 |
(*) | 5,384,868 shares of common stock were sold pursuant to the ATM Agreement for aggregate proceeds of $26.6 million, net of commissions and fees.
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL | SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODEL
|  | September 30, 2025 |  |  | September 30, 2024 |
Expected volatility |  |  | 84.01% – 84.01 | % |  |  | 90.41% – 136.11 | %
Risk-free interest rate |  |  | 4.57% – 4.57 | % |  |  | 3.78% – 4.79 | %
Stock price on date of grant |  | $ | 6.97 – $6.97 |  |  | $ | 31.28 – $31.28 |
Dividend yield |  |  | 0.00 | % |  |  | 0.00 | %
Expected term |  |  | 1 year |  |  |  | 1 to 5 years |
SCHEDULE OF COMMON STOCK OUTSTANDING | Changes in common stock options for the nine months ended September 30, 2025 and 2024 were as follows: SCHEDULE OF COMMON STOCK OUTSTANDING
|  | Number of Options Outstanding and Vested |  |  | Weighted Average Exercise Price |  |  | Remaining Contractual Life (Years) |  |  | Aggregated Intrinsic Value |
Outstanding and vested, January 1, 2025 |  |  | 40,667 |  |  | $ | 0.2041 |  |  |  | 3.44 |  |  | $ | 249,122 |
Issued (1) |  |  | 439,996 |  |  |  | 0.0077 |  |  |  |  |  |  |  |  |
Outstanding and vested, September 30, 2025 |  |  | 480,663 |  |  | $ | 0.0243 |  |  |  | 4.88 |  |  | $ | 2,276,256 |
|  | Number of Options Outstanding and Vested |  |  | Weighted Average Exercise Price |  |  | Remaining Contractual Life (Years) |  |  | Aggregated Intrinsic Value |
Outstanding and vested, January 1, 2024 |  |  | 50,667 |  |  | $ | 15.9474 |  |  |  | 2.40 |  |  | $ | 776,864 |
Issued (2) |  |  | 429,996 |  |  |  | 0.0077 |  |  |  |  |  |  |  |  |
Expired and cancelled (3) |  |  | (40,000 | ) |  |  | 20.00 |  |  |  |  |  |  |  |  |
Outstanding and vested, September 30, 2024 |  |  | 440,663 |  |  | $ | 0.0256 |  |  |  | 8.49 |  |  | $ | 2,985,208 |
1) | In the nine months ended September 30, 2025, 439,996 common stock options were issued with a grant date fair value of $3,066,772.
2) | In the nine months ended September 30, 2024, 429,996 common stock options were issued with a grant date fair value of $13,447,502.
3) | In the nine months ended September 30, 2024, 40,000 common stock options were cancelled upon expiry.
SCHEDULE OF WARRANT ASSUMPTION | SCHEDULE OF WARRANT ASSUMPTION
|  | September 30, 2025 |
Expected volatility |  |  | 85.43% - 85.43% |
Risk-free interest rate |  |  | 4.54% - 4.54% |
Stock price on date of grant |  | $ | 6.45 - $6.45 |
Dividend yield |  |  | 0.00 | %
Expected term |  |  | 2 years |
SCHEDULE OF WARRANT ACTIVITY | Changes in common stock purchase warrants for the nine months ended September 30, 2025 were as follows: SCHEDULE OF WARRANT ACTIVITY
|  | Number of Warrants Outstanding and Vested |  |  | Weighted Average Exercise Price |  |  | Weighted Average Contractual Life (Years) |  |  | Aggregated Intrinsic Value |
Outstanding and vested, January 1, 2025 |  |  | 16,668 |  |  | $ | 10.4999 |  |  |  |  | 0.79 |  |  | $ | - |
Warrants Issued (1) |  |  | 75,000 |  |  | $ | 8.1250 |  |  |  |  |  |  |  |  |  |
Expired |  |  | (6,667 | ) |  |  | 15.000 |  |  |  |  |  |  |  |  |  |
Outstanding and vested, September 30, 2025 |  |  | 85,001 |  |  | $ | 9.2280 |  |  |  |  | 1.95 |  |  | $ | - |
1) | The warrants issued in the nine months ended September 30, 2025 had a total grant date fair value of $200,981.
SCHEDULE OF CHANGE IN RESTRICTED STOCK UNITS | Changes in RSUs for the nine months ended September 30, 2025 and September 30, 2024 were as follows: SCHEDULE OF CHANGE IN RESTRICTED STOCK UNITS
|  | Number of RSUs Outstanding |
Outstanding at January 1, 2025 |  |  | 572,476 |
Granted (1) |  |  | 313,903 |
Vested (2) |  |  | (340,403 | )
Forfeited (3) |  |  | (13,750 | )
Outstanding at September 30, 2025 |  |  | 532,226 |
|  | Number of RSUs Outstanding |
Outstanding at January 1, 2024 |  |  | 1,040,017 |
Granted (4) |  |  | 458,653 |
Vested (5) |  |  | (622,961 | )
Expired or cancelled (6) |  |  | (60,000 | )
Forfeiture (7) |  |  | (371,709 | )
Outstanding at September 30, 2024 |  |  | 444,000 |
1) | In the nine months ended September 30, 2025, 313,903 RSUs were granted to officers and consultants of the Company, with a total grant date fair value of $1,684,293 as measured at an average $5.37/share trailing to the date the RSU was granted, as follows: (i) 270,903 RSUs which immediately vested upon grant and (ii) 43,000 RSUs with time-based vesting of four years.
2) | In the nine months ended September 30, 2025, 340,403 RSUs vested and were settled through the issuance of 340,403 shares of common stock.
3) | In the nine months ended September 30, 2025, 13,750 RSUs were forfeited upon termination of employment and service agreements with former executives and consultants of the Company.
4) | In the nine months ended September 30, 2024, 458,653 RSUs were granted to officers and consultants of the Company, with a total grant date fair value of $5,025,195 as measured at $11.36/share using the Company’s 20-day volume weighted average price trailing to the date the RSU was granted, as follows: (i) 69,980 RSUs which immediately vested upon grant and (ii) 388,673 RSUs with time-based vesting over periods ranging from six months to four years.
5) | In the nine months ended September 30, 2024, 622,961 RSUs vested and were settled through the issuance of 622,961 shares of common stock.
6) | In the nine months ended September 30, 2024, 60,000 RSUs were cancelled without vesting because the performance conditions for vesting were not met..
7) | In the nine months ended September 30, 2024, 371,709 RSUs were forfeited upon termination of employment and service agreements with former executives and consultants of the Company.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the change in common stock outstanding. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of sales of stock or previously unissued stock made by subsidiary or equity method investee to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity. + References No definition available. + Details
Name: | us-gaap_ScheduleOfSaleOfStockBySubsidiaryOrEquityMethodInvesteeDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration